Zimmer Biomet Holdings Inc (NYSE:ZBH) – Equities research analysts at Cantor Fitzgerald issued their FY2017 earnings estimates for shares of Zimmer Biomet in a report issued on Sunday. Cantor Fitzgerald analyst C. Bijou expects that the medical equipment provider will post earnings per share of $8.03 for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Zimmer Biomet’s FY2018 earnings at $8.15 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a return on equity of 3.82% and a net margin of 5.43%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.79 earnings per share.

Several other brokerages also recently weighed in on ZBH. Royal Bank of Canada cut their price target on Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a report on Tuesday, November 7th. SunTrust Banks set a $136.00 price target on Zimmer Biomet and gave the company a “buy” rating in a report on Wednesday, November 1st. Morgan Stanley cut their price target on Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. BMO Capital Markets cut their price target on Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, November 2nd. Finally, Deutsche Bank upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $137.42.

Zimmer Biomet (NYSE ZBH) opened at $122.29 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $24,760.00, a price-to-earnings ratio of 38.10, a price-to-earnings-growth ratio of 1.96 and a beta of 1.15. Zimmer Biomet has a twelve month low of $108.03 and a twelve month high of $133.49.

A number of institutional investors have recently made changes to their positions in ZBH. Bank of Nova Scotia Trust Co. purchased a new stake in Zimmer Biomet during the 3rd quarter worth $112,000. FNY Managed Accounts LLC purchased a new stake in Zimmer Biomet during the 3rd quarter worth $117,000. Steward Partners Investment Advisory LLC purchased a new stake in Zimmer Biomet during the 3rd quarter worth $140,000. BB&T Investment Services Inc. purchased a new stake in Zimmer Biomet during the 2nd quarter worth $144,000. Finally, Sandy Spring Bank boosted its position in Zimmer Biomet by 5.4% during the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 66 shares during the period. 85.92% of the stock is owned by hedge funds and other institutional investors.

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet’s dividend payout ratio (DPR) is 29.91%.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-to-post-fy2017-earnings-of-8-03-per-share-cantor-fitzgerald-forecasts/1803802.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with Analyst Ratings Network's FREE daily email newsletter.